Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

more+
SELECT FILTER
 
Close

PUBLICATION DATE

624 results
Display

Hepatitis B vaccination and immunotherapies: an update

Stasi C, Silvestri , Voller F

World Health Organization (WHO) estimates that 257 million people were living with chronic hepatitis B virus (HBV) infection. Highest HBV prevalence was found in the WHO Western Pacific Region (6.2%)...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Tenofovir and Entecavir Have Similar Renal Adverse Events on Hepatocellular Carcinoma Patients Treated with Transarterial Chemoembolization

Cho YY, Choi YH, Yu SJ, Cho EJ, Lee JH, Kim YJ, Yoon JH

BACKGROUND/AIMS: Tenofovir disoproxil fumarate (TDF) is potentially nephrotoxic in chronic hepatitis B patients. Hepatocellular carcinoma (HCC) patients treated using transarterial chemoembolization (TACE) are at an increased risk of renal injury....
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Influence of hepatic steatosis on the outcomes of patients with chronic hepatitis B treated with entecavir and tenofovir

Kim DS, Jeon MY, Lee HW, Kim BK, Park JY, Kim DY, Ahn SH, Han KH, Kim SU

BACKGROUND/AIMS: The influence of hepatic steatosis (HS) on chronic hepatitis B (CHB) is unclear. We evaluated the influence of the degree of HS, assessed using the controlled attenuation parameter (CAP)...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
How does hepatic steatosis affect the outcome of patients with chronic hepatitis B?

Yu JH, Lee JW

No abstract available.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Hepatocellular carcinoma surveillance in the 21st century: Saving lives or causing harm?

Hanouneh I, Alkhouri N, Singal AG

Hepatocellular carcinoma (HCC) is the third most common cause of cancer related death worldwide. Prognosis and treatment options largely depend on tumor stage at diagnosis, with curative treatments only available...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
The epidemiology of hepatitis B virus infection in Korea

Yim SY, Kim JH

The global burden of hepatitis B virus (HBV) infection is profound, and represents a public health threat as chronic infection can lead to liver cirrhosis, hepatocellular carcinoma, and death. The...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
2018 Korean Liver Cancer Association–National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma

Korean Liver Cancer Association (KLCA), National Cancer Center (NCC), Goyang, Korea

Hepatocellular carcinoma (HCC) is the fifth most common cancer globally and the fourth most common cancer in men in Korea, where the prevalence of chronic hepatitis B infection is high...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Efficacy of long-term tenofovir disoproxil fumarate therapy in chronic hepatitis B patients with partial virologic response in real practice

Song JE, Lee CH, Kim BS

BACKGROUND/AIMS: The optimal management of chronic hepatitis B (CHB) patients with partial virologic response (PVR) to tenofovir disoproxil fumarate (TDF) remains unclear. We aimed to evaluate the long-term efficacy of...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Are the Patients in the Immune Tolerant Phase of Chronic Hepatitis B far from Hepatocellular Carcinoma or Death?

Heo NY

No abstract available.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Evaluation of Noninvasive Liver Fibrosis Blood Markers in Patients with Chronic Hepatitis B and Hepatitis C

Lee JH, Cho J, Kim J, Uh Y, Youn KJ

BACKGROUND: Liver fibrosis evaluation is an important issue in chronic liver disease patients. We aimed to develop noninvasive liver fibrosis biomarkers based on transient elastography (TE, FibroScan®) through retrospective review...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Unmet need in chronic hepatitis B management

Liang LY, Wong GL

Despite all these exciting developments, there remain some unmet needs in the management for patients with chronic hepatitis B (CHB). As majority of CHB patients are going to use oral...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
KASL clinical practice guidelines for management of chronic hepatitis B

Korean Association for the Study of the Liver (KASL)

No abstract available.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Updated Treatment of Chronic Hepatitis B

Yoon EL, Yim HJ

Chronic hepatitis B virus (HBV) infection is a major cause of liver cirrhosis and hepatocellular carcinoma in Korea. The prevalence of HBV infection is gradually decreasing in Korea, but 3.0%...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
2018 Korean Liver Cancer Association–National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma

Korean Liver Cancer Association (KLCA) and National Cancer Center (NCC), Korea. klca@livercancer.or.kr, jwpark@ncc.re.kr

Hepatocellular carcinoma (HCC) is the fifth most common cancer globally and the fourth most common cancer in men in Korea, where the prevalence of chronic hepatitis B infection is high...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Gallbladder Fistula Treated with N-Butyl-2-Cyanoacrylate after Radiofrequency Ablation in a Hepatocellular Carcinoma Patient: a Case Report

So IT, Jang BK, Hwang JS, Kim YH

Radiofrequency ablation (RFA) is a minimally invasive local therapy for hepatocellular carcinoma (HCC). Even though RFA is considered to be a safe treatment modality, a variety of complications have been...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Discrepancy between the Actual Clinical Status of Patients with Hepatocellular Carcinoma and Expectations from Hepatocellular Carcinoma Surveillance: a Single-Center Study

Kim NM, Doh YS, Jang JW, Kim SH, Eun HS, Jun JH, Kim SH, Baek IH, Jung SH

BACKGROUND/AIMS: The National Liver Cancer Screening Program (NLCSP) has been implemented for the past 15 years in Korea. However, the actual clinical experience in Korea is inconsistent with the expectations...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Association between hepatic steatosis and the development of hepatocellular carcinoma in patients with chronic hepatitis B

Lee YB, Ha Y, Chon YE, Kim MN, Lee JH, Park H, Kim KI, Kim SH, Rim KS, Hwang SG

BACKGROUND/AIMS: Nonalcoholic fatty liver disease (NAFLD) is becoming a worldwide epidemic, and is frequently found in patients with chronic hepatitis B (CHB). We investigated the impact of histologically proven hepatic...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Liver Cirrhosis, Not Antiviral Therapy, Predicts Clinical Outcome in Cohorts with Heterogeneous Hepatitis B Viral Status

Kim MN, Hwang SG, Kim BK, Park JY, Kim DY, Han KH, Kim SU, Ahn SH

BACKGROUND/AIMS: Antiviral therapy (AVT) reduces the risk of hepatocellular carcinoma (HCC) development in patients with chronic hepatitis B (CHB). This multicenter retrospective study investigated the effects of AVT and hepatitis...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
2018 Korean Association for the Study of the Liver (KASL) Clinical Practice Guidelines of Chronic Hepatitis B: What's Different?

Kim JH

The clinical practice guideline for the management of chronic hepatitis B (CHB) was originally enacted in 2004 by the Korean Association for the Study of the Liver in order to...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Diagnostic Performance of Serum Asialo-α1-acid Glycoprotein for Advanced Liver Fibrosis or Cirrhosis in Patients with Chronic Hepatitis B or Nonalcoholic Fatty Liver Disease

Kim SU, Jeon MY, Lim TS

BACKGROUND/AIMS: The utility of asialo-α1-acid glycoprotein (AsAGP) for assessing the fibrotic burden is unknown. This study examined the diagnostic performance of the AsAGP level for advanced liver fibrosis or cirrhosis...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2021 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr